← Back to Screener
Apollomics Inc. Class A Ordinary Shares (APLM)
Price$14.00
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-25.52%
Price vs S&P 500 (4W)-11.94%
VGM Score28.61
Market Capitalization$30.74M
All Metrics
Book Value / Share (Quarterly)$4.41
P/TBV (Annual)3.44x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$8.57
Price vs S&P 500 (YTD)-31.73%
EPS (TTM)$-18.93
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-18.93
EPS (Annual)$-7.57
ROI (Annual)-923.81%
Cash / Share (Quarterly)$1.53
ROA (Last FY)-162.93%
EBITD / Share (TTM)$-18.01
Cash Flow / Share (Annual)$-4.83
P/B Ratio6.32x
P/B Ratio (Quarterly)2.21x
Net Income / Employee (Annual)$-781,400
Net Interest Coverage (TTM)-142.89x
ROA (TTM)-263.28%
EPS Incl Extra (Annual)$-7.57
Current Ratio (Annual)0.96x
Quick Ratio (Quarterly)0.88x
3-Month Avg Trading Volume0.01M
52-Week Price Return-91.47%
Tangible BV / Share (Quarterly)$2.84
P/S Ratio (Annual)3.62x
Asset Turnover (Annual)1.27x
52-Week High$42.12
EPS Excl Extra (Annual)$-7.57
26-Week Price Return-17.60%
Quick Ratio (Annual)0.88x
13-Week Price Return-30.59%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)0.96x
Enterprise Value$28.11M
Revenue / Employee (Annual)$607,100
Pretax Margin (Annual)-128.66%
Cash / Share (Annual)$1.53
3-Month Return Std Dev75.02%
Net Income / Employee (TTM)$-1,676,800
ROE (Last FY)-1107.28%
EPS Basic Excl Extra (Annual)$-7.57
EV / Free Cash Flow (TTM)1.53x
Total Debt / Equity (Quarterly)0.20x
EPS Incl Extra (TTM)$-18.93
ROI (TTM)-567.60%
Revenue / Share (Annual)$5.88
Tangible BV / Share (Annual)$2.84
Price vs S&P 500 (52W)-92.51%
Year-to-Date Return-25.11%
5-Day Price Return-2.30%
EPS Normalized (Annual)$-7.57
ROA (5Y Avg)-177.31%
Net Profit Margin (Annual)-128.69%
Month-to-Date Return-1.06%
Cash Flow / Share (TTM)$-0.02
EBITD / Share (Annual)$-7.58
Operating Margin (Annual)-131.79%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)1.67x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-18.93
P/TBV (Quarterly)3.44x
P/B Ratio (Annual)2.21x
Book Value / Share (Annual)$4.41
Price vs S&P 500 (13W)-38.84%
Beta1.36x
ROE (TTM)-693.39%
52-Week Low$3.66
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Sep 2024
Oct 2024
Nov 2024
Dec 2024
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
APLMApollomics Inc. Class A Ordinary Shares | — | — | D | $14.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Apollomics is a clinical-stage biopharmaceutical company developing oncology therapies designed to enhance immune function and target specific molecular pathways. The company's lead programs include vebreltinib (APL-101), a c-Met inhibitor for non-small cell lung cancer and other c-Met-altered tumors, and uproleselan (APL-106), an E-Selectin antagonist being evaluated in combination with chemotherapy for acute myeloid leukemia.